Can the positive effects of adiponectin binding to its receptors be used in treating obese and insulin resistant patients as well as patients with obesity induced non-alcoholic fatty liver disease (NAFLD) or the more severe non-alcoholic steatohepatitis (NASH)? This evidence concerns the gene ADIPOQ and Obesity.